Gallagher hails from the School of Pharmacy at Temple University in Pennsylvania where he serves as the director of the residency program and clinical professor and clinical pharmacy specialist in infectious disease.
Throughout his esteemed career, Gallagher has been responsible for publications, abstracts and book chapters.
He has been the president of the Society of Infectious Diseases Pharmacists and has had leadership positions in other societies.
Gallagher is an author of Antibiotics Simplified, which is it its fourth edition, and currently serves on the Infectious Diseases Specialty Council of the board of Pharmacy Specialties.
His research interests focus on pharmacotherapy of resistant infections, antimicrobial clinical pharmacodynamics, and antibiotic stewardship.
As editor in chief, Gallagher will work closely with Contagion's editorial team to deliver information about recent medical developments and research in infectious diseases.
Additionally, Dr. Gallagher will offer exclusive insights about emerging trends in the infectious disease community.
Contagion is a news resource covering all areas of infectious disease.
Through its website, quarterly journal, email newsletters, social media outlets and Outbreak Monitor, it provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment and prevention of infectious diseases.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial